AstraZeneca

A robot arm from ABB on display at Automatica 2023 in Munich. (Photo: Sven Hoppe/dpa/Getty Images)
Newsletters

SoftBank will acquire ABB’s robotics business

By
October 9, 2025
AstraZeneca begins European exit—will invest $50 billion in the U.S. amid tariff threats
Politics

AstraZeneca begins European exit—will invest $50 billion in the U.S. amid tariff threats

By
July 22, 2025
U.K. business leaders are ‘struggling to see what’s business-friendly’ about Labour
Politics

U.K. business leaders are ‘struggling to see what’s business-friendly’ about Labour

By Jamie Nimmo, Irina Anghel, Jennifer Creery and Bloomberg
July 7, 2025
New London IPOs hit 28-year low amid AstraZeneca exit concerns
Economy

New London IPOs hit 28-year low amid AstraZeneca exit concerns

By Pablo Mayo Cerqueiro, Joe Easton, Neil Campling and Bloomberg
July 3, 2025
AstraZeneca CEO hopes U.S. will represent half of company’s global revenue by 2030—vows to invest and expand in nation despite tariff threat
Finance

AstraZeneca CEO hopes U.S. will represent half of company’s global revenue by 2030—vows to invest and expand in nation despite tariff threat

By
April 29, 2025
AstraZeneca to buy cell therapy biotech for up to $1 billion
Tech

AstraZeneca to buy cell therapy biotech for up to $1 billion

By Ashleigh Furlong and Bloomberg
March 17, 2025
AstraZeneca sees profits surge despite Chinese import tax allegations
Health

AstraZeneca sees profits surge despite Chinese import tax allegations

By
February 6, 2025
Eli Lilly & Co., the Coins2Day 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
Health

Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says

By
January 22, 2025
Ryanair ceo Michael O'Leary sitting by a table
Success

Ryanair’s Michael O’Leary, who is up for a $108 million bonus, doesn’t see high CEO pay as a problem: ‘Footballers are getting half a million a week’

By
January 10, 2025
Lynparza (olaparib), a product of Coins2Day 500 pharmaceutical firm Merck and Coins2Day 500 Europe company AstraZeneca, showed meaningful improvements in overall survival in people with germline BRCA-mutated (gBRCAm), HER2-negative high-risk early breast cancer, 2024 clinical trial data suggest.
Health

Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows

By
December 20, 2024
AstraZeneca says it’s taking China’s investigations into fraud, illegal drug importation and data collection ‘very seriously’
Retail

AstraZeneca says it’s taking China’s investigations into fraud, illegal drug importation and data collection ‘very seriously’

By
November 12, 2024
AstraZeneca’s China chief detained in illegal data collection and drug import probe, pharma giant says
Leadership

AstraZeneca’s China chief detained in illegal data collection and drug import probe, pharma giant says

By
November 7, 2024
AstraZeneca’s drive for China dominance in focus as chief probed
Finance

AstraZeneca’s drive for China dominance in focus as chief probed

By Amber Tong and Bloomberg
October 31, 2024
Pascal Soriot, chief executive officer of AstraZeneca Plc.
Retail

AstraZeneca sets bold revenue target as CEO aims to double sales to $80 billion by 2030

By Ashleigh Furlong and Bloomberg
May 21, 2024
AstraZeneca pulls its COVID-19 vaccine from European market after history of stumbles
Health

AstraZeneca pulls its COVID-19 vaccine from European market after history of stumbles

By
May 9, 2024

Most Popular